Search company, investor...
Trius Therapeutics company logo

Trius Therapeutics

Founded Year



Acq - P2P | Acquired

Total Raised




About Trius Therapeutics

Trius Therapeutics is discovering and developing antibacterial drugs for the treatment of life-threatening infections. The company's lead product candidate, TR-701 is a oral and IV oxazolidinone antibiotic with potent activity against Gram positive bacterial pathogens. Trius' pipeline includes three additional structure-based drug design programs directed against antibacterial targets.

Headquarters Location

6310 Nancy Ridge Drive Suite 101

San Diego, California, 92121,

United States


Missing: Trius Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Trius Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Trius Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Trius Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Trius Therapeutics Patents

Trius Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Prodrugs, Transcription factors, Antibiotics, Piperazines, DNA replication


Application Date


Grant Date



Related Topics

Prodrugs, Transcription factors, Antibiotics, Piperazines, DNA replication



Latest Trius Therapeutics News

Cidara Therapeutics to Host Research and Development Day

Jun 27, 2022

June 27, 2022 08:00 ET San Diego, California, UNITED STATES Virtual panel discussion will highlight the company’s Cloudbreak® platform and its potential advantages in oncology Event to be held on Thursday, July 7th at 10 AM ET SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will host a virtual research and development day on Thursday, July 7, 2022, at 10:00 AM Eastern Time. The virtual event will feature a panel discussion with oncology key opinion leaders, Ezra Cohen, M.D., FRCPSC, FASCO, San Diego Center for Precision Immunotherapy, and Perry Nisen, M.D., Ph.D., CEO and Executive Chairman of Quanta. The panel discussion will be focused on Cidara’s Cloudbreak® platform, which couples potent inhibitors to a human antibody fragment to create highly potent, long-acting drug-Fc conjugates (DFCs) designed to simultaneously inhibit multiple disease targets. Cidara has been developing Cloudbreak since 2018 and entered into a platform-validating collaboration agreement with Janssen Pharmaceuticals, Inc. in April 2021 for the development of CD388, currently in Phase 1 studies, for the universal prevention and treatment of influenza. The panel will highlight the principles behind the Cloudbreak DFC approach, contrast it with antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), and small molecule applications and will review the potential advantages of DFCs in oncology. New data emerging from Cidara’s SARS-CoV-2 and oncology DFC programs in the immune checkpoint blockade pathway will be featured. A question-and-answer session will follow. To register for the event please click here . Ezra Cohen, M.D., FRCPSC, FASCO is the Chief of the Division of Hematology-Oncology, and Co- Director of the San Diego Center for Precision Immunotherapy. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in investigating the mechanisms of action of novel therapeutics and made major contributions to the development of targeted- and immuno-therapies. His research in areas such as epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer has received peer-reviewed funding. He has made major contributions to the understanding of critical signaling pathways, the integration of novel agents into standard of care, and to the defining of mechanisms to overcome resistance to drug therapy. He also recently co-developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti-tumor immune response. Dr. Cohen also serves as Associate Director for Clinical Science, Co-Leader of the Solid Tumor Therapeutics Research Program and Co-Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center at Moores Cancer Center. Additionally, he is a member of the Protocol Review and Monitoring Committee (PRMC), the Cancer Council, and the Cancer Center’s Executive Committee. Perry Nisen, M.D., Ph.D. became CEO of Quanta Therapeutics in June 2021 after having served as the founding Executive Chairman of the company during its formation in his role as Executive Partner at Sofinnova Investments beginning in 2018. He is a physician scientist with extensive experience in drug discovery and development, with particular interest in oncology. Perry is the former CEO of the Sanford Burnham Prebys Medical Discovery Institute (SBP). As CEO, he was responsible for all aspects of the organization, including strategy, operations and performance. Prior to SBP, he held multiple senior leadership positions during his tenure at GlaxoSmithKline (GSK), including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head. Responsibilities at GSK included all aspects of drug discovery, clinical development, risk/benefit and operations. Before GSK, Perry was the Divisional Vice President, Cancer Research then Oncology Clinical Development at Abbott Laboratories. Prior to industry, he was the Lowe Foundation Professor at the University of Texas Southwestern Medical Center. Perry holds a BS from Stanford University, and MD/PhD from the Albert Einstein College of Medicine. He is also an independent Director of TEVA Pharmaceuticals, and chair of their science and technology committee. Les Tari, Ph.D. serves as Chief Scientific Officer of Cidara Therapeutics and is the principal inventor of the Cloudbreak DFC approach. Dr. Tari has over 19 years of experience in early stage drug discovery in both industry and academia. He has led a number of discovery programs and is an author or inventor on over 50 publications and patents. Previous to Cidara, Dr. Tari held positions of increasing responsibility at Trius Therapeutics from 2007 until its acquisition by Cubist Pharmaceuticals in 2013. At Trius, Dr. Tari led the efforts to generate and advance a novel class of dual-targeting broad spectrum antibacterial agents. Prior to Trius, Dr. Tari was a co-founder and Director of Structural Biology from 2003 to 2007 at ActiveSight Inc., where he led all research efforts in inflammation and oncology. From 2001 until 2003, Dr. Tari was a member of the scientific staff during the start-up phase of Syrrx Inc., where he participated in the design and development of the first industrial high-throughput structural genomics platform that aided in the discovery of Alogliptin, subsequently approved for the treatment of type II diabetes. Previous to his career in industry, Dr. Tari held an academic position as an Alberta Heritage Foundation Scholar for Medical Research at the University of Calgary, where he conducted research focused on antibiotic discovery. Dr. Tari holds a B.Sc. in Chemistry, and a Ph.D. in Chemistry and Structural Biology from the University of Manitoba. About Cidara Therapeutics Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing prevention and treatment paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak platform. Cidara is headquartered in San Diego, California. For more information, please visit Forward-Looking Statements This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “look forward to,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies, among other things, and in this release include, but are not limited to, statements related to the potential for influenza DFCs, including CD388, to provide universal prevention against seasonal and pandemic influenza, intentions to provide further updates on the CD388 program, the timing of the NDA filing for rezafungin with the FDA and other regulators outside the U.S. and the ability of the Company’s product portfolio to transform existing prevention and treatment paradigms. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s preclinical or clinical trials, delays in action by regulatory authorities due to limitations on inspections and other COVID-19-related effects, and impacts of the COVID-19 pandemic or other obstacles on the enrollment of patients or other aspects of CD388 development. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. INVESTOR CONTACT:

Trius Therapeutics Frequently Asked Questions (FAQ)

  • When was Trius Therapeutics founded?

    Trius Therapeutics was founded in 2004.

  • Where is Trius Therapeutics's headquarters?

    Trius Therapeutics's headquarters is located at 6310 Nancy Ridge Drive, San Diego.

  • What is Trius Therapeutics's latest funding round?

    Trius Therapeutics's latest funding round is Acq - P2P.

  • How much did Trius Therapeutics raise?

    Trius Therapeutics raised a total of $79.5M.

  • Who are the investors of Trius Therapeutics?

    Investors of Trius Therapeutics include Cubist Pharmaceuticals, Defense Threat Reduction Agency, Prism VentureWorks, Sofinnova Ventures, InterWest Partners and 5 more.

  • Who are Trius Therapeutics's competitors?

    Competitors of Trius Therapeutics include Arena Pharmaceuticals, Inhibikase Therapeutics, Tarsa Therapeutics, Midway Biome, Nabriva Therapeutics and 16 more.

Compare Trius Therapeutics to Competitors

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Lytix Biopharma

Pre clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing. oncology

Topica Logo

Topica provides marketing and sales solutions for businesses with online channels. Topica's solution enables businesses and organizations world-wide to find new prospective customers and sell more online. Using Topica, online marketers better leverage their current marketing initiatives, such as paid search, affiliate programs and display advertising, as they turn more traffic into first-time buyers and loyal long term customers.

Valderm Aps

Valderm ApS is focused on the development of the second generation anthracycline valrubicin for once daily topical treatment of hyperproliferative skin diseases e.g. psoriasis.


ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.